Table 1. Choices of management strategies for persistent febrile neutropenia in various high-risk patient groups, presented in 3 clinical scenarios to the participants of 13 children’s hospitals in the UK.

Clinical scenarios	Empiric strategy	Pre-emptive strategy
Allogenous HSCT recipient	85% (11/13)	54% (7/13)
Acute leukemia (i.e. high risk ALL, AML)	82% (9/11)	40% (4/10)
SAA/MDS	82% (9/11)	40% (4/10)

HSCT: Hematopoietic Stem Cell Transplantation, ALL: Acute Lymphoblastic Leukemia; AML, Acute Myeloid Leukemia, SSA: sever aplastic anemia, MDS: myelodysplastic syndrome.